ReviewMolecular medicine reports2021
Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review).
Review in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Article
- Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors.Cancer research communications · 2026Article
- A combined hematological and molecular study of Hodgkin lymphoma in Palestine: insights into subtype-specific prognosis and the role of Claudin-6/GATA-4.Annals of hematology · 2026Article
- Prognostic and Predictive Significance of Claudin-6 Expression in Advanced-Stage High-Grade Serous Ovarian Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy.Journal of nanobiotechnology · 2026Article
- Treatment options in platinum-refractory male germ cell cancers: current standards and future directions.Therapeutic advances in medical oncology · 2026Review
- Involvement of claudins 6 and 9 in epithelial-mesenchymal transition and the metastatic process.Tissue barriers · 2026Review
- Antibody-drug conjugates and beyond in platinum-resistant ovarian cancer: A comprehensive review of emergent strategies.Therapeutic advances in medical oncology · 2026Review
- Optimizing CAR T cell therapy for solid tumours: a clinical perspective.Nature reviews. Clinical oncology · 2025Review
- Tight junction disruptionWorld journal of clinical oncology · 2025Article
- Review
- Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion.American journal of ophthalmology case reports · 2025Article
- Uncovering biomarkers and pathways in oral squamous cell carcinoma through integrated lncRNA-mRNA regulatory network analysis.Discover oncology · 2025Article
- Expanding the potential of antibody-drug conjugates in gastrointestinal malignancies: beyond HER2 targets.ESMO gastrointestinal oncology · 2025Review
- Biophysical basis of tight junction barrier modulation by a pan-claudin-binding molecule.PNAS nexus · 2025Article
- Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.Experimental hematology & oncology · 2025Review
- Guided Differentiation of Pluripotent Stem Cells into Heterogeneously Differentiating Cultures of Cardiac Cells.bioRxiv : the preprint server for biology · 2025Article
- Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.Frontiers in molecular medicine · 2025Review
- Advances in Tumor Antigen Vaccines: A New Frontier in Cancer Immunotherapy.International journal of medical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tight junctions (TJs) are an important component of cell connectivity; they maintain cell polarity, permeability and adhesion, and participate in the regulation of cell proliferation and differentiation. The claudin (CLDN) family is integral to TJs, and CLDN6 is an important member of this family. Abnormal expression of CLDN6 can destroy the integrity of TJs through various mechanisms and can serve multiple roles in the occurrence and development of tumours. CLDN6 is widely expressed in various tumours but rarely expressed in healthy adult tissues. The aim of this review is to critically examine the recent literature on CLDN6, including its structure, expression in different tumours, regulatory mechanisms and therapeutic prospects. Although some conclusions are controversial, in certain tumours, such as liver, ovarian, endometrial and oesophageal cancer, and atypical teratoid/rhabdoid tumours, research consistently shows that CLDN6 is expressed in tumour tissues but is not expressed or is expressed at low levels in surrounding tissues. In these tumours, CLDN6 has potential as a carcinoembryonic antigen and a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.